| Dr Edward S Thomas, MD | |
|
390 Toll Gate Rd, Ste 108, Warwick, RI 02886-4326 | |
| (401) 739-7210 | |
| Not Available |
| Full Name | Dr Edward S Thomas |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 42 Years |
| Location | 390 Toll Gate Rd, Warwick, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154327245 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| South County Hospital Inc | Wakefield, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Entity Name | Kent County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386643294 PECOS PAC ID: 2668377078 Enrollment ID: O20040628000569 |
News Archive
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Every American hospital has two front doors: The real one, and an imaginary revolving door.
› Verified 2 days ago
| Entity Name | Kent Cardiology Assoc Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285791640 PECOS PAC ID: 3173694361 Enrollment ID: O20080616000431 |
News Archive
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Every American hospital has two front doors: The real one, and an imaginary revolving door.
› Verified 2 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Every American hospital has two front doors: The real one, and an imaginary revolving door.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward S Thomas, MD 390 Toll Gate Rd Ste 202, Warwick, RI 02886-4326 Ph: (401) 739-7210 | Dr Edward S Thomas, MD 390 Toll Gate Rd, Ste 108, Warwick, RI 02886-4326 Ph: (401) 739-7210 |
News Archive
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Every American hospital has two front doors: The real one, and an imaginary revolving door.
› Verified 2 days ago
Dr. Sterling Leaf Malish, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7000 | |
Dr. John David Lowney, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1030 Warwick Ave, Warwick, RI 02888 Phone: 401-467-6257 Fax: 401-785-1191 | |
Dr. Christian Rene Herard, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 300 Tollgate Road, Suite 302, Warwick, RI 02886 Phone: 401-738-4014 Fax: 401-738-4090 | |
John A Gelzhiser, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7000 Fax: 401-736-4265 | |
Dr. Michael Seidler, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 125 Metro Center Blvd Ste 2000, Warwick, RI 02886 Phone: 401-921-9202 Fax: 401-921-9212 | |
Murli K Raman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 455 Tollgate Rd, Brigham & Women's Cardiovascular Associates At Cne, Warwick, RI 02886 Phone: 401-681-4996 Fax: 401-921-6569 | |
Dr. Jennifer F Jarbeau, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 400 Bald Hill Rd Ste 524, Warwick, RI 02886 Phone: 401-737-7313 Fax: 401-737-4207 |